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1School of Chemistry, University of Southampton, Highfield, Southampton, United KingdomABSTRACT The multidrug and toxic compound extrusion transporters extrude a wide variety of substrates out of both
mammalian and bacterial cells via the electrochemical gradient of protons and cations across the membrane. The substrates
transported by these proteins include toxic metabolites and antimicrobial drugs. These proteins contribute to multidrug resis-
tance in both mammalian and bacterial cells and are therefore extremely important from a biomedical perspective. Although spe-
cific residues of the protein are known to be responsible for the extrusion of solutes, mechanistic details and indeed structures of
all the conformational states remain elusive. Here, we report the first, to our knowledge, simulation study of the recently resolved
x-ray structure of the multidrug and toxic compound extrusion transporter, NorM from Neisseria gonorrhoeae (NorM_NG). Mul-
tiple, atomistic simulations of the unbound and bound forms of NorM in a phospholipid lipid bilayer allow us to identify the nature
of the drug-protein/ion-protein interactions, and secondly determine how these interactions contribute to the conformational re-
arrangements of the protein. In particular, we identify the molecular rearrangements that occur to enable the Naþ ion to enter the
cation-binding cavity even in the presence of a bound drug molecule. These include side chain flipping of a key residue, GLU-261
from pointing toward the central cavity to pointing toward the cation binding side when bound to a Naþ ion. Our simulations also
provide support for cation binding in the drug-bound and apo states of NorM_NG.INTRODUCTIONBacterial multidrug transporters are membrane proteins that
extrude antibiotics and other toxic compounds from within
bacterial cells to the external milieu. In doing so, they
play a major role in the development of bacteria that exhibit
multidrug resistance, causing a serious problem for public
healthcare, worldwide (1).
Multidrug transporters are divided into five main groups
(2): the major facilitator superfamily (3), the small multi-
drug resistance family (4), the resistance nodulation cell
division family, the ATP binding cassette family (5), and
the multidrug and toxic compound extrusion (MATE)
family. The MATE family is the latest to be identified,
thus the last to be included into the multidrug efflux trans-
porter families (6). Of the identified MATE proteins, there
are only 24 that are functionally characterized and they
are widely distributed in all kingdoms of living organisms,
including humans, bacteria, and plants (7). The MATE
transporters are secondary transport systems; they use the
difference in the electrochemical potential of Hþ or Naþ
ions across the membrane to drive drug transport. Exam-Submitted March 6, 2014, and accepted for publication June 2, 2014.
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0006-3495/14/07/0460/9 $2.00ples in humans are hMATE1 and hMATE2 transporters
in which the final step in the excretion of metabolic waste
and xenobiotic organic cations are carried out through
electron exchange of Hþ in the kidney (8,9). In plants,
MATE transporters are responsible for detoxification of
secondary metabolites, including alkaloids through ex-
change of both Naþ and Hþ ions (7,10), in contrast, most
MATE transporters identified in bacteria, including NorM
from Vibrio cholera (NorM_VC) (11), NorM from Vibrio
parahaemolyticus (NorM_VP) (12), and NorM from Neis-
seria gonorrhoeae (NorM_NG) (13), export drug mole-
cules through Naþ ion exchange.
In this work, we focus our attention on the bacterial
MATE transporter, NorM. The first x-ray structure of
NorM to be determined was from V. cholera. It was deter-
mined at a resolution of 3.65 A˚ with the protein in its out-
ward-facing ion-bound, drug-free state (Protein Data Bank
(PDB) code: 3MKT). In this outward-facing conformation,
a V-shaped channel is formed by transmembrane helices
(TM) 1 and 8 on one side and TM 2 and 7 on the other
side. As a result, the central cavity is open to the extracel-
lular side allowing extrusion of substrate (11). Molecular
dynamics (MD) simulations initiated from this structure
by Vanni et. al. (14), revealed a loss in the V-shape of the
NorM extracellular vestibule due to several hydrophobic
residues in the outer parts of TM 1 and 2 and TM 7 and 8
forming direct interactions with each other and extruding
water molecules from the lumen. As a result, water and
Naþ ions could only access the cation-binding site withinhttp://dx.doi.org/10.1016/j.bpj.2014.06.005
MD Simulations of a Bacterial MATE Transporter 461the protein through a narrow permeation pathway. In addi-
tion, they also suggested that there are two distinct modes
of Naþ ion binding (competitive and simultaneous) in the
cation-binding site, which could be crucial for inducing
the conformational change from the outward-facing to the
inward-facing state. The loss of the vestibule V-shape was
also reported from a similar MD study by Song et al. (15).
Interestingly, in contrast to Vanni et al., the authors of this
study suggested that two Naþ ions bind to the cation-bind-
ing site of NorM_VC.
Recently, four x-ray structures of NorM_NG (from
N. gonorrhoeae) have been determined. All of the structures
have a resolution of ~3.6 A˚ and capture the protein in its out-
ward-facing conformation with a drug molecule, tetraphe-
nylphosphonium (TPP) present in the central cavity of the
protein (PDB codes: 4HUK, 4HUM, and 4HUN). One of
the structures also reveals a Naþ ion present in the cation-
binding site (PDB code: 4HUL) (16). Interestingly, superim-
position of the NorM_VC x-ray structure, which represents
a cation-bound and drug-free state, with the NorM_NG
crystal structure (drug-bound and cation-free state), re-
vealed that helices TM 7 and TM 8 moved ~0.6 nm away
from the central cavity, toward helix TM 10 (16). It has
been hypothesized that the binding of Naþ to the cation-
binding site, which is located at the C-terminal end of the
protein, and is formed by residues GLU-261, TYR-294,
and ASP-377 from TM7, TM8, and TM10, respectively,
could play a role in this conformational rearrangement of
the TM helices. These structures combined with the
NorM_VC structures enabled Lu et. al. (16) to propose an
antiport mechanism of transport, in which there are six
distinct states; three in each of the outward-facing and in-
ward-facing conformations.
They proposed that initially the protein in its outward-
facing, drug-bound, ion-free state (PDB codes: 4HUK,
4HUM, and 4HUN) takes in Naþ ions from the extracel-
lular side, mediated by residues GLU-261 and TYR-294.
Once the Naþ ion is in the cation-binding site (as in the
structure PDB code: 4HUL), a conformational change
occurs. TM7 and TM8 move toward TM10, which in
turn enables residue ASP-377 to form an electrostatic
interaction with the Naþ ion. This conformational rear-
rangement results in disruption of protein-drug interac-
tions, specifically those involving residues PHE-265,
GLN-284, and SER-288. This triggers the extrusion of
the bound drug into the periplasmic space. After the
drug is extruded, the ion-bound, drug-free transporter
(3MKT) undergoes a more substantial conformational
rearrangement, to the inward-facing state, from which it
can capture another drug molecule. Upon drug binding,
TM7 and TM8 move back to the central cavity, followed
by release of the Naþ ion from the binding site into
the cytoplasm. The drug-bound, ion-free transporter then
rearranges into the outward-facing conformation that com-
pletes the mechanistic cycle.Despite the clearly plausible and elegant mechanism
put forward by Lu et al., the structures of NorM_NG do raise
some questions concerning the outward-facing phase of the
proposed antiport mechanism. First, the presence of the drug
molecule in the central cavity of the transporter may provide
an obstacle for the passage of the Naþ ion into the cation-
binding site. A previous simulation study showed the Naþ
ion moves into the binding site through a narrow permeation
pathway without the drug molecule present in the central
cavity (14). Thus, the effect of the drug on ion binding is still
unresolved. Second, although the x-ray structures reveal
specific conformation states that comprise the transport
cycle of the antiport mechanism, the precise conformational
rearrangement events that provide the transitions between
these states, remain elusive.
From a mechanistic perspective, characterizing the dy-
namics of the protein are important in identifying any
conformational changes that may occur to enable cation
binding. In particular, in terms of the mechanism proposed
earlier, we may ask are cations able to bind after the drug-
binding event? This would provide further support for the
idea that cation-binding triggers drug extrusion.
To address these questions, we have carried out multiple
atomistic molecular dynamics simulations of the NorM_NG
transporter in a palmitoyloleoylphosphatidylcholine (POPC)
lipid bilayer. Our results provide molecular-level details of
drug and ion binding to NorM_NG. Moreover, our simula-
tions provide further evidence for the proposed antiport
mechanism in which the ion-binding event leads to drug
extrusion from the outward-facing state of the protein in
the final phase of the transport cycle.MATERIALS AND METHODS
The x-ray structure was obtained from the PDB with the PDB code 4HUK
(16). Parameters for the TPP drug were obtained using automated topology
builder (17). The protein-drug complex was embedded into a POPC lipid
bilayer using the GROMACS utility g_membed (18).
Atomistic simulations were performed using GROMACS version 4.5.1
(19–21). The simulations used the united-atom GROMOS 54A7 force field
(22) with POPC lipids adapted from the Berger parameters (23). Water
molecules were treated explicitly using the SPC water model (24). 502
POPC lipids, 30,739 water molecules were present in the simulation sys-
tems with a simulation box size of 12.5  12.5  10 nm in the x, y, and z
dimensions, respectively. The equivalent of 100 mM of sodium and chlo-
ride ions were added to the simulation systems. Additional ions were
added to ensure all systems were charge neutral. Ionizable side chains
were modeled in their default states at neutral pH. All lipid and protein
bonds were constrained using the LINCS algorithm (25) and waters
were constrained using the SETTLE algorithm (26), allowing for a time
step of 2 fs to be used. Energy minimization was performed using the
steepest descent algorithm for 1000 steps to remove any overlapping con-
tacts. Position restraints with 1000 kJ mol1 nm2 were applied to the Ca
of the protein for the first 10 ns of certain simulations (see Table 1) to
allow a reequilibration of the solvent around the protein. The Nose´-Hoover
thermostat, with a time constant for the coupling of 0.5 ps, was used to
maintain the system temperature at 298 K (27). The Parrinello-Rahman
barostat, with a time constant of 5.0 ps, was used to maintain the system
pressure at 1.0 bar (28). Electrostatic interactions used a cut-off of 1 nmBiophysical Journal 107(2) 460–468
TABLE 1 Table of all the simulations performed
Simulation
Simulation
time
(nanosecond)
First
10 ns
with
RESa
Drug present
in central
cavity of
protein
100 mM NaCl
present
in bulk
of system
unbound_v1 210 Yes No No
unbound_v2 210 Yes No No
unbound_v3 210 Yes No No
bound_v1 210 Yes Yes No
bound_v2 210 Yes Yes No
bound_v3 210 Yes Yes No
unbound_ion_v1 210 Yes No Yes
unbound_ion_v2 210 Yes No Yes
unbound_ion_v3 210 Yes No Yes
bound_ion_v1 500 Yes Yes Yes
bound_ion_v2 500 Yes Yes Yes
bound_ion_v3 500 Yes Yes Yes
bound_ion_v4 200 No Yes Yes
bound_ion_v5 200 No Yes Yes
bound_ion_v6 200 No Yes Yes
bound_two_ion_v1 500 Yes Yes Yes
bound_two_ion_v2 200 Yes Yes Yes
bound_two_ion_v3 200 Yes Yes Yes
ProtE261_D377_v1 210 Yes No Yes
ProtE261_D377_v2 210 Yes No Yes
ProtE261_D377_v3 210 Yes No Yes
Mutant_D41A_v1 210 Yes No Yes
Mutant_D41A_v2 210 Yes No Yes
Mutant_D41A_v3 210 Yes No Yes
aPositional restraints were applied on the Ca atoms of the protein for the
first 10 ns.
462 Leung et al.with interactions beyond this cutoff treated using the smooth particle mesh
Ewald method (29). The van der Waals interactions also used a cut-off of
1 nm with a long-range dispersion correction applied for the energy and
pressure. The neighbor list was updated every 5 steps. The components
of all the simulations are summarized in Table 1. All the simulations
were performed on the Iridis-4 supercomputer at the University of South-
ampton. DSSP and GROMACS tools were used to determine the confor-
mation properties of the NorM_NG (30). Visualization of simulation
trajectories was conducted in VMD (31). An additional set of simulations
was performed to study the effect of the charge state of residues GLU-261
and ASP-377, where ProtE261_D377v1-3 refer to simulations in which
both GLU-261 and ASP-377 are protonated. Finally, the D41A mutant
was also simulated (Mutant_D41Av1-3), given experimental data showed
this mutant completely abolished transport activity (16). Three indepen-
dent simulations of each protonated system and the mutant were
performed.Biophysical Journal 107(2) 460–468RESULTS AND DISCUSSION
Structural drift and fluctuations
To evaluate the conformational stability of the protein
structure on the timescale of the simulations, the structural
drift was measured via calculation of the root mean-square
deviation (RMSD) from the initial starting structure of
NorM_NG over multiple simulations. In all of the simula-
tions, the RMSD values reached a plateau value between
~50 to 100 ns. In general, the greatest deviation was
observed in loops 3–4 and 9–10, although the most stable
secondary structural elements were the TM helices 1–12
(Figs. S1–S3 in the Supporting Material). Specifically, in
all three sets of simulations, loops 3–4, 6–7, and 9–10,
had plateau RMSD values of ~0.5 nm after 20 ns, whereas
the RMSD of the other loops and helices TM1-12 remained
at ~0.2–0.3 nm throughout the 200 ns simulation (Figs. S1–
S3). These large variations in the RMSDs between loops
3–4, 6–7, and 9–10 and the other loops indicate a greater
degree of flexibility in the former. Block analysis (32) of
the RMSD values over the final 50 ns of the simulations
showed that the standard error of the mean converged for
block sizes of >20 ns, indicating converged trajectories
(Fig. S4). Encouragingly, a previous MD simulation study
suggested that loops 3–4 and 9–10 are likely to play an
important role in the process of drug extrusion (16).
After position restraints were removed from the protein,
we observed partial collapse of the V-shape extracellular
vestibule of NorM_NG, in agreement with the two previous
simulation studies of NorM_VC (14,15) (Fig. 1). Further-
more, analysis of the all-to-all RMSDs of the protein re-
vealed that even after 210 ns of simulation, the overall
three-dimensional architecture of the protein continued to
undergo conformational drift (Fig. S5), suggesting there
may be more than one energetically favored state. In further
support of this hypothesis, simulations of NorM_VC (mul-
tiple repeats including simulations using a different force
field for lengths of up to 1 ms; see the Supporting Material
for more information) also revealed the continued increase
in protein conformational drift (Fig. S6).
To explore these changes in conformation of the
NorM_NG protein, the stability of the secondary structureFIGURE 1 Snapshot of the simulation system
before the equilibration step (left) shows the x-
ray structure of the protein, NorM-NG, and the
drug molecule, TPP, embedded in a POPC bilayer.
The system after 500 ns of simulation is shown in
the panel on the right. The amino (1–6 TM helices)
and carboxyl (7–12 TM helices) terminal domains
of the protein are colored green and yellow, respec-
tively. TPP is colored in red. The letters ‘‘N’’ and
‘‘C’’ indicate the amino and carboxyl terminal of
the protein. The gray spheres indicate the POPC
lipid headgroups. Water and ions in the system
are omitted for clarity. To see this figure in color,
go online.
MD Simulations of a Bacterial MATE Transporter 463was evaluated using the DSSP analysis code (30). Encourag-
ingly, results showed all of the TMs retained their a-helical
conformation throughout the simulations (Fig. 1 and Fig,
S7). Having established the stability of the protein second-
ary structure on the timescale of the simulations, we sought
to investigate the interactions between the drug and ion with
the protein to gain insight into the role they play in this out-
ward-facing phase of the proposed mechanism. However,
before the investigation of these interactions, we performed
additional analysis to ascertain if there were any conforma-
tional rearrangements of the region of the protein implicated
in drug and ion binding (see Table S1) (16). RMSD analysis
(including all-to-all RMSDs) of this region revealed that
these regions were not subject to structural drift over the
timescale of the simulations (Fig. S5). This provided confi-
dence that the continued changes in protein conforma-
tion were not impacting upon the observed drug and ion
interactions.Movement of NaD ion
X-ray structures of the outward-facing conformation of
NorM transporters reveal a monovalent cation-binding site
in the protein. Given that NorM transporters exploit either
a Naþ or Hþ gradient across the membrane to drive sub-
strate export, to determine the sequence of events in the
transport process we may ask if ions are able to enter the
cation-binding site once the drug is bound. Experimental ev-
idence indicates this may be the case; x-ray structures from
the apo-NorM crystals soaked in solution containing Csþ
(Naþ analog) revealed a Csþ binding site located outside
the drug-binding cavity. Of importance, the x-ray structure
did not show significant conformational deviation from the
cation-free, TPP-bound NorM_NG structure (RMS devia-
tion of 0.05 nm), used to initiate our simulations (16). To
explore the movement of Naþ once TPP is already bound
the center of mass motion of Naþ ions was monitored
throughout the simulations (Fig. 2). It is worth reiterating
here that the equivalent of 100 mM of NaCl ions were added
to certain simulation systems (see Table1). In general, we
observe a pathway through the protein to the cation-binding
site that is lined by aspartate residues, specifically residues
ASP-52, ASP-355, ASP-356, and ASP-41. The Naþ ion
initially binds (where bind is defined as a protein-ion dis-
tance of %0.3 nm) to ASP-52 in loop L1-2, subsequently
it rapidly (within 1 ns) moves toward residues ASP-355,
ASP-356, and then ASP-41, where it associates with each
one in turn before entering the cation-binding site (Fig. 2
and Fig. S8).
In all three simulations unbound_ion_v1-3 (no TPP) dur-
ing the first 10 nanoseconds of the simulation, while the Ca
of the protein is still subjected to positional restraints, a sin-
gle Naþ ion was observed to move into the cation-binding
site, through the previously described aspartate pathway,
in agreement with a similar computational study (14). Incontrast, in simulations bound_ion_v1–6 (in which TPP is
present), a Naþ ion moved into the cation-binding site in
two out of the six simulations (bound_ion_v2 and v3). In
the other four simulations, the TPP molecule appears to
physically obstruct movement of Naþ into the cation-bind-
ing site. In all of our six simulations, whether the Naþ ion
ended up moving into the cation-binding site or not, we
observed the ion first bound to ASP-41 before entering the
central cavity, indeed the presence of TPP appears to guide
movement of the ion toward ASP-41 (Fig. 3).
The Naþ ion remained within 0.3 nm of ASP-41 for over
5 ns in simulation bound_ion_v1 and v3. In simulation boun-
d_ion_v2, Naþ ion moved away from ASP-41 as it moved
into the cation-binding site after 3 ns. In the same simulation,
as a Naþ ion approached the cation-binding site it interacted
with residue GLU-261. The side chain of residue GLU-261
was initially pointing toward the central cavity, however
upon interaction with the Naþ ion, it flipped toward the
cation-binding site, thereby facilitating the movement of
the ion associated with it, into the binding site. Within one
nanosecond of entering the cation-binding site, the ion inter-
acted with residues TYR-294 and ASP-377, although still
being bound to GLU-261 (Fig. 2). We also observed flipping
of the GLU-261 side chain, and interactions with TYR-294
and ASP-377 in simulations unbound_ion_v1 to v3 when
the ion moves into the binding site. Of importance, in simu-
lations (bound_ion_v1 and bound_v1-6) in which Naþ does
not bind, flipping of GLU-261 toward the cation-binding site
is not observed (Fig. 4). However, there is some flexibility of
the side chain such that it deviates slightly from the x-ray
structure. To further investigate the importance of the spe-
cific protein-cation interactions, we studied NorM_NG in
an additional ionization state; with GLU-261 and ASP-377
both protonated (rather than charged) in three independent
simulations (ProtE261_D377v1-3). In all three simulations
a Naþ ion was observed to enter the central cavity of the pro-
tein. However, the Naþ ion was not observed tomove into the
cation-binding site in any of these simulations. In fact, in two
of the three simulations (v2 and v3), the Naþ ion moved out
of the central cavity and subsequently exited the protein
completely after ~40 and ~20 ns, respectively. Encourag-
ingly, experimental studies have indicated that these residues
are responsible for binding and stabilizing the ion in the
binding site; Lu et al. showed that NorM_NG mutants
E261A and Y294L were unable to decrease the sensitivity
of the bacterium toward drugs like ethidium and TPP. This
was hypothesized to be most likely due to the loss of the
transport function of the protein (16). In another mutational
study of the NorM_VC D371N (equivalent to ASP-377 of
NorM_NG), the binding of Naþ was completely abolished
(11). In addition, mutations to GLU-261, in NorM_VP
GLU-251, and hMATE1 GLU-273 also inhibited substrate
transport activity (8,33,34).
To investigate the importance of ASP-41, we per-
formed three independent simulations of the D41A mutantBiophysical Journal 107(2) 460–468
FIGURE 2 The middle panel of the left column
shows five stages of the movement of the Naþ ion
within the first 10 ns of bound_ion_v2 simulation.
The Naþ ion moves into the central cavity and
subsequently the cation-binding site from the
extracellular space, via a pathway that involves
electrostatic interactions with five different ASP
residues. The other panels show close-up views
of specific Naþ- ASP interactions. Water mole-
cules within 0.3 nm of the ion are also shown.
The simulation times at which the snapshots are
extracted are stated at the top left corner of the
panels. The protein is yellow, Naþ ion is green,
ASP-52 is pink, ASP-356 is gray, ASP-355 is
blue, ASP-41 is cyan, GLU-261 is purple, TYR-
294 is tan, ASP-377 is orange, and water is red
and white. The brown lines indicate the lipid head-
groups. Part of TM2 and loop 3 and 4 of the pro-
tein, lipid tails, other water molecules, and ions
in the system are omitted for clarity. To see this
figure in color, go online.
464 Leung et al.(Mutant_D41A_v1-3). In two out of three simulations (v1
and v3), not a single Naþ ion is observed to bind in the
cation-binding site. In v1 a Naþ ion was observed to move
into the central cavity of the protein, after which it subse-
quently oscillated between the central cavity and cation-
binding site, never remaining in the cation-binding site
for >10 ns at a time. In v3, the Naþ ion moved out of the
protein in the first 10 ns of the simulation, and no other
Naþ ion was observed to enter the central cavity of the pro-
tein during the remainder of the simulation. In contrast, in
simulation v2, a single Naþ ion was observed to move
into the cation-binding site via GLU-261 and remained in
the site forming interactions with GLU-261, TYR-294,
and ASP-377 throughout the remaining 200 ns of simula-
tion. Taken together, these simulation results suggest a
reduced affinity for Naþ ions when ASP-41 is mutated. Pre-
vious experimental mutational studies have reported theBiophysical Journal 107(2) 460–468efflux activity of NorM_NG toward the drug molecule
Rhodamine 6G, which is completely abolished in D41A.
Based on the experimental observations, our simulations
and the previously proposed mechanisms of drug extrusion,
we hypothesize that the molecular origins of abolition of
drug transport activity in D41A may be that the disruption
of the interactions between residues on TM 7 (PHE-265)
and 8 (SER-288), and the drug molecule, that lead to drug
extrusion in the wild-type protein are inhibited in the low
cation-affinity mutant.
Water molecules in the binding site provide additional
stabilizing interactions with the Naþ ion. In the unbound
protein, ~50 water molecules move into the interior of the
protein, from the extracellular side within the first 2 ns of
the simulation. Approximately 40 of the water molecules
are located within the central cavity, and 10 or so are in
the cation-binding site. Within the cation-binding site,
FIGURE 3 The Naþ ion moves readily into the cation-binding site via
the central cavity. Figure shows the movement of the Naþ ion into the
cation-binding site. The spheres represent the location of the ion during
the first 10 ns of simulation bound_ion_v2. Red, white, blue color scheme
is used, red is at the start of the simulation, and blue is at time ¼ 10 ns. The
protein backbone is shown in tube representation and is colored yellow. The
drug is shown in gray. The brown lines indicate the lipid headgroups.
Lipids, water, and other ions in the system are omitted for clarity. To see
this figure in color, go online.
MD Simulations of a Bacterial MATE Transporter 465although the Naþ is bound to residues GLU-261, TYR-294,
and ASP-377 as described previously, it is also coordinated
by 2–4 water molecules (Fig. 2). Interestingly, even in the
presence of the drug molecule, TPP, a similar number of
water molecules were observed to enter the protein interior
as the unbound simulations, with stabilization of the Naþthrough a combination of interactions with the protein and
water molecules. The results presented here not only pro-
vide further support for the functional relevance of the
cation-binding site of NorM_NG (11,16,33) but also reveal
the molecular-level details of the dynamics of the interplay
between the protein residues, water molecules, and the Naþ
ion. Our hypothesis is that GLU-261 is the residue respon-
sible for bringing Naþ ions into the cation-binding site
from the central cavity, whereas TYR-294, ASP-377, and
water molecules provide stabilizing interactions that anchor
the cation within the binding site.The drug may play a role in binding and
stabilization of the ion within the cation-binding
site
Given we do observe a Naþ ion entering the cation-binding
site, even in the presence of the bound drug molecule (in two
out of six simulations, specifically bound_ion_v2 and boun-
d_ion_v3), we may ask if the drug plays a role in stabilizing/
destabilizing the ion. To explore this, we have examined the
molecular processes that occur subsequent to the ASP-41-
Naþ binding event. The drug molecule, TPP binds to
PHE-265 (in TM7) within 1 ns of the start of the simulations
(Fig. S9). In doing so, the TPP moves ~0.2 nm toward the
central cavity of the protein, in particular toward TM7,
from its initial position in the x-ray structure (Fig. 3). This
movement of the drug toward TM7 seems to be a key step
for Naþ movement into the cation-binding site. Although
the TPP molecule is in its original position as in the x-ray
structure, it prevents interaction of the Naþ and GLU-261.FIGURE 4 Snapshots showing the change in the
orientation of the side chain of GLU-261. The
panel on the top shows the position of GLU-261
in apo NorM_NG. The black circles correspond
to the approximate position of the cation-binding
site. The panel on the bottom left is a zoomed in
view of GLU-261 from simulation bound_v1.
The bottom right panel is taken from the boun-
d_ion_v2 simulation, showing the side chain of
GLU-261 pointing toward the cation-binding site
with a Naþ ion present in the cation-binding site.
The protein is shown in a yellow tube representa-
tion, GLU-261 is shown in a sticks representation,
Naþ ion is green, and TPP gray. Water molecules,
lipids, and other ions are omitted for clarity. To see
this figure in color, go online.
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466 Leung et al.Once it has moved closer to TM7, an unobstructed pathway
from the solvent to the cation-binding site is created,
enabling the Naþ to interact with the side chain of GLU-
261 and subsequently move past the drug, into the binding
site.
In simulations unbound_ion_v1-3, in which TPP was not
present, Naþ ion moved into the cation-binding site during
the first 10 ns of the simulation. In these simulations after
the initial binding of the Naþ ion within the cation-binding
site, it was observed to move in and out of the this site
throughout the course of simulation. Whereas in simulation
bound_ion_v2 and v3, after the ion was bound within the
binding site, it remained in the site more readily than
observed in the absence of drug in the unbound_ion simula-
tions. In the transport mechanism stated from previous
experimental study by Lu and co-workers (16), the drug
would be present when Naþ ion moved into the cation-
binding site, and it is the binding of Naþ ion to the binding
site that causes drug extrusion by disrupting interactions
between the drug and TM 7 and 8 of the protein. In addition,
in simulation bound_ion_v2, the drug moved slightly away
from PHE-265 after the ion bound to the binding site
(Fig. S9), to be positioned more centrally in the central cav-
ity. From this observation, it seems that there is a possibility
that the drug could play a role in ion stabilization by ob-
structing the pathway leading away from the binding site.Two NaD ion binding mode of NorM
Previously, a binding mode in which two Naþ ions occupy
the cation-binding site of NorM_VC has been proposed
(15). MD simulations indicated that this two-ion-binding
might contribute to the induced conformational change of
NorM_VC from the outward-facing to the inward-facing
conformation. In all of our unbound_ion and bound_ion
simulations, only one Naþ ion is present at any given
time, within the binding site. Whereas in the bound_ion_v1FIGURE 5 Three snapshots taken from simulation 3MKT_apo_v1 showing the
(purple) interacting with GLU-255 (silver) and ASP-371 (cyan) in the cation-bin
20 ns of the simulation. The panel in the middle shows the Naþ ion, which was or
The cation-binding site contains two-ions at this point (~40 ns). The panel on th
cation-binding site, is extruded into the central cavity. To see this figure in colo
Biophysical Journal 107(2) 460–468simulation, physical obstruction by the drug, prevented even
one ion entering the cation-binding site. To explore the pos-
sibility of two Naþ ions occupying the cation-binding site in
NorM_NG, we performed three additional simulations, this
time with two ions in the cation-binding site. A system snap-
shot was extracted after 10 ns from the bound_ion v2 simu-
lation and a second ion was manually placed within the
cation-binding site. Three independent simulations of this
system revealed that only one ion remains permanently
within the binding site. The second ion was observed to
move away from the binding site after 5–20 ns, and out of
the protein completely into the bulk solvent after ~80 ns.
Interestingly, the presence of the drug did not prevent the
movement of the ion into, or out of the cation-binding
site, in other words it did not obstruct the path of the ion.
The single remaining Naþ ion occupied the binding site
throughout the remainder of the respective simulations.
For comparative analysis of the ion dynamics of MATE
transporters, we also performed simulations of the x-ray
structure of NorM_VC, PDB code 3MKT (see Table S2).
In each of the three simulations, we observed one Naþ ion
entering the cation-binding site during the equilibration
stage of simulation. In two of the simulations, a second
Naþ ion was observed to enter the binding site from the
central cavity after further ~35 and ~100 ns, respectively.
The two ions simultaneously occupied the binding site
for between ~2 and 5 ns, after which one ion moved out
(Fig. 5). In one of the two-ion-binding simulations, another
ion was observed to enter the central cavity after ~10 ns
of the initial two-ion-binding event, from where it
subsequently moved into the cation-binding site. This sec-
ond two-ion-binding state was short-lived; lasting only
~0.5 ns, after which one Naþ ion was extruded. The previ-
ous observations are in qualitative agreement with previous
simulation studies of this protein and suggest that the two-
ion-binding mode does exist in NorM_VC and may be
an intermediate state with a possible role in TM helixcompetitive binding of two Naþ ions. The panel on the left shows a Naþ ion
ding site, and another Naþ ion (green) in the central cavity of the protein at
iginally in the central cavity, having also moved into the cation-binding site.
e right shows that after a further ~2 ns the Naþ ion that was initially in the
r, go online.
MD Simulations of a Bacterial MATE Transporter 467rearrangements that lead to conformational change of NorM
(15). In contrast, the evidence for a two-ion-binding state is
less convincing for NorM_NG, and if it does exist, it is
likely to be very short-lived.
It is important to consider the methodological limitations
of the current studies. Perhaps the primary limitation of
the simulations is the relatively short duration (>200 ns)
of the MD calculations. Longer simulations would improve
the sampling of the protein conformational dynamics. How-
ever, to some extent we have addressed this by performing
multiple simulations of each system. Despite this limitation,
the current study is encouraging in that it enables the ration-
alization of experimental observations and shows that con-
ventional atomistic simulations may be applied to identify
solute permeation pathways through membrane proteins,
and indeed in this case allows us to propose one part of a
transport mechanism (Fig. 6).CONCLUSIONS
In conclusion, we have identified the pathway taken by
a monovalent cation to enter the cation-binding site of
NorM_NG, and the key intermolecular interactions that sta-
bilize this ion within the binding site. We have shown that
the presence of a bound drug molecule does not prevent
movement of the ion into the binding site, but may in fact
even stabilize it. The stabilization of the ion in the binding
site is likely to cause the protein to proceed to the drug
extrusion stage. Our simulations suggest that a two-ion
binding state is more likely in NorM_VC than NorM_NG.
Thus, our simulation study has added some of the hitherto
missing pieces of the puzzle represented by the mechanism
of the NorM transport cycle. It is important to note that
future extensions of the current study would involve consid-
eration of a membrane model that better mimics the in vivo
environment of NorM_NG, both in terms of lipid content
and the crowded protein environment, indeed such complexFIGURE 6 Schematic representation of the proposed mechanism of action of
protein from the extracellular side (state 1). Once the Naþ ion is in the cation-bind
the interaction between residues PHE-265 with the drug molecule (orange ellips
mechanism, the x-ray structure of NorM-NG (PDB code 4HUK) represents state
brown lines indicate the lipid headgroup region of the bilayer. The yellow line rep
thin red line represents TM10. The blue arrows indicate the approximate positi
color, go online.membrane models have already been reported for eukary-
otic (35) and prokaryotic organisms (36,37).SUPPORTING MATERIAL
Nine figures, two tables, and supporting data are available at http://www.
biophysj.org/biophysj/supplemental/S0006-3495(14)00607-9.
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